Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.Relatlimab has a blocking effect, blocking the interaction of LAG-3/MHC II (IC50: 0.67 nM) and LAG-3/FGL1 (IC50: 0.019 nM). Relatlimab is often used with Nivoluma to treat advanced melanoma.

Relatlimab (0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and macaque CD4+ T cells with EC50 values of 0.11 nM and 29.11 nM, respectively.[1]
Relatlimab (0.001-10000 nM; 3A9-hLAG-3) enhances peptide reactivity of T-cell hybridoma 3A9-hLAG-3 and reverses lag-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 Effect, IC50 value is 1.05 nM.[1]
Relatlimab (0.001-10000 nM; primary T cells) enhances activation and enhances IL-2 secretion in superantigen-stimulated human PBMC cultures.[1]

Human

Monoclonal

Unconjugated